alexa Regulatory Considerations For Regenerative Therapeutics: US Perspective
ISSN: 2157-7552

Journal of Tissue Science & Engineering
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

8th International Conference on Tissue Science and Regenerative Medicine
September 11- 12, 2017 Singapore

Debra Aub Webster
Cardinal Health Regulatory Sciences, USA
Keynote: J Tissue Sci Eng
DOI: 10.4172/2157-7552-C1-035
Abstract
The regulation of human cells and tissues by the United States Food and Drug Administration (FDA) originated with the 1902 Biologics Control Act and the 1944 Public Health Service (PHS) Act. These initial acts were put into place to ensure purity of serum and vaccines and to control the spread of communicable diseases, respectively. As the use of human cells and tissues has expanded, FDA was faced with the dilemma of differentiating between their uses in the practice of medicine versus in the manufacture of a product. Under the authority of Section 361 of the PHS Act, FDA introduced a comprehensive regulatory program in 1997 for human cells, tissues and cellular and tissue-based products (HCT/Ps). This consolidated regulatory approach covered all cells and tissues and was tiered and risk-based to allow for less regulatory evaluation of products determined to present a minimal risk to patient safety. In 2005, this regulatory program was implemented in rules codified under 21 CFR Section 1271. These rules defined the conditions that must be met for an HCT/P to be regulated solely under the PHS Act (called 361 HCT/Ps) and those that would be defined as biological products that would also be regulated under the Food, Drug and Cosmetic Act requiring market clearance (called 351 HCT/Ps). This determination and the potential regulatory pathways for these cutting edge technologies is often complex and understanding these regulatory pathways and the definitions surrounding them is critical to successful product development in the United States. Beyond the challenges of navigating the regulatory maze for new regenerative therapeutics, sponsors must also adopt new approaches to evaluate safety and efficacy, and to identify measurable quality attributes regarding product safety, quality and potency. FDA is actively engaged in providing guidance and expedited approval pathways in order to bring these discoveries safely forward to benefit patients.
Biography

Debra Aub Webster has over 20 years of experience in pharmaceutical research and the regulatory environment. She has started her regulatory career with the US FDA as Reviewing Toxicologist/Pharmacologist. As a Principal Scientist in Regulatory Affairs and Product Development with Cardinal Health Regulatory Sciences, she leads projects for biologic and regenerative medicine product development programs. In this capacity, she provides guidance on clinical, nonclinical and regulatory aspects of strategic product development, author’s regulatory documents and acts as the Regulatory Representative for sponsors in interactions with the FDA.

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords